Inferra AI / Company / TEVA
Teva Pharmaceutical Industries
TEVA · Health Care
Last earnings Sep 3, 2026
Key results
Revenuequarter
$3.9 billion
Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
AJOVY global revenues of $139 million in Q1 2025, an increase of 26% in local currency terms compared to Q1 2024.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
UZEDY continues strong momentum global revenues of $39 million in Q1 2025.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Operating marginquarter
30%
Transforming Teva: Targeted programs to deliver~$700 million of net savings, after incremental reinvestment behind growth, to transform Teva into a modern biopharmaceutical company and achieving 30% operating margin target in 2027.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Revenues of $3.9 billion GAAP diluted EPSof $0.18
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Non-GAAP EPSquarter
$0.52
Non-GAAP diluted EPS of $0.52, an increase of $0.04 or 8% year-over-year Cash flow used in operating activities of $105 million
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Richard Francis, Teva's President and CEO, said, Teva had a solid start to the year, with its ninth consecutive quarter of revenue growth, delivering global revenues of $3.9 billion, an increase of 5% in local currency terms compared to the first quarter of 2024.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Our key innovative growth drivers continue to show strong momentum, collectively generating revenues of $589 million while each growing more than 25% year over year.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
AI analysis
Q1 2025 · reported May 7, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · May 7, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q1 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $3.9 billion | — | — |
| Operating margin | 30% | — | — |
| Non-GAAP EPS | $0.52 | — | — |
Guidance · company-stated
Direction: Raised
“AUSTEDO shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.”
“Reaffirming $600M 2025 revenue outlook.”
“With these results, we are revising our 2025 outlook and reaffirming our 2027 targets.”
Classified from the release's primary full-year outlook statement.
Margin
Capital allocation
Our ongoing efforts to allocate capital appropriately include debt repayment of $1.4 billion at maturity, our recently completed divestment of our business venture in Japan, our intention to divest our API business through a sale, and ongoing programs to improve working capital efficiency.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue -89.5% computed from stated figures
Event summary
Teva Pharmaceutical Industries Q1 2025 — Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%.
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “AUSTEDO shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.”
Revenue: “Reaffirming $600M 2025 revenue outlook.”
Revenue — Raised (“increase”)
“AUSTEDO shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.”
Revenue — Reiterated (“Reaffirming”)
“Reaffirming $600M 2025 revenue outlook.”
Company outlook — Reiterated (“reaffirming”)
“With these results, we are revising our 2025 outlook and reaffirming our 2027 targets.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Our ongoing efforts to allocate capital appropriately include debt repayment of $1.4 billion at maturity, our recently completed divestment of our business venture in Japan, our intention to divest our API business through a sale, and ongoing programs to improve working capital efficiency.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
As of March 31, 2025, our debt was $16,651 million, compared to $17,783 million as of December 31, 2024.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
The portion of total debt classified as short-term as of March 31, 2025 was 3% compared to 10% as of December 31, 2024.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Our average debt maturity was approximately 5.7 years as of March 31, 2025, compared to 5.5 years as of December 31, 2024.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Outlook for 202 5 Non-GAAP Results $ billions, except EPS or as noted January 2025 Outlook May 2025 Outlook Revenues* $16.8 - $17.4 $16.8 - $17.2 AUSTEDO ($m)* 1,900-2,050 1,950-2,050 AJOVY ($m)* ~600 ~600 UZEDY ($m)* ~160 ~160 COPAXONE ($m)* ~370 ~370 Operating Income 4.1 - 4.6 4.3 - 4.6 Adjusted EBITDA 4.5 - 5.0 4.7 - 5.0 Tax Rate 15%-18% 15%-18% Finance Expenses ~0.9 ~0.9 Diluted EPS ($) 2.35 - 2.65 2.45 - 2.65 Free Cash Flow** 1.6 1.9 1.6 1.9 CAPEX* ~0.5 ~0.5 Foreign Exchange Volatile swings in FX can negatively impact revenue and income * Revenues and CAPEX presented on a GAAP basis.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
** Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Strategy & priorities
com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Teva to host Innovation & Strategy Day on Thursday, May 29 in New York, NY.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Francis continued, Now entering the Acceleration Phase of our Pivot to Growth Strategy, we have a clear roadmap to continue Teva's transformation into a leading biopharmaceutical company with an expected 30% operating margin and today have announced ~$700 million net savings by 2027.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Pivot to Growth Strategy In Q1 2025, we continued to execute on the four key pillars of our Pivot to Growth strategy, which we announced in May 2023.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Sustaining Our Generic s Powerhouse - under the third pillar, we remained focused on strengthening our position as a global leader in generic medicines with a streamlined portfolio, robust pipeline, integrated manufacturing and global commercial footprint.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Risks & headwinds
tariffs expected to have immaterial impact; absorbed in updated 2025 non-GAAP outlook.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
(2) This outlook is based on the existing tariff and trade environment as of May 7, 2025, and does not reflect any policy shifts, including pharmaceutical sector tariffs, that could impact business.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
In certain countries, Teva remains in litigation against generic companies regarding COPAXONE.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
(5) Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to the rationalization of our plants, accelerated depreciation, certain inventory write-offs, material litigation fees and other unusual events.
SEC original ↗Teva Pharmaceutical Industries — Earnings release (8-K exhibit)EX-99May 7, 2025
Legal Proceedings 80 Item 1A.
SEC original ↗Teva Pharmaceutical Industries — 10-Q Quarterly report10-QJul 29, 2026
Given Teva s global operations, including personnel and several manufacturing and R&D facilities in Israel, as well as its exposure to international markets, continued instability in the region could adversely impact Teva s business operations and financial condition.
SEC original ↗Teva Pharmaceutical Industries — 10-Q Quarterly report10-QJul 29, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
61 documents- Q3 2026
- 8-KTEVA
- Q2 2026
- 8-KTEVA
- 8-KTEVA
- 8-KTEVA
- 8-KTEVA
- 8-KTEVA
- 10-QTEVA
- 8-KTEVA
- Q1 2026
- 8-KTEVA
- 10-QTEVA
- 8-KTEVA
- Q4 2025
- 10-KTEVA
- 8-KTEVA
- 8-KTEVA
- Q3 2025
- 8-KTEVA
- 10-QTEVA
- 8-KTEVA
- Q2 2025
- 10-QTEVA
- 8-KTEVA
- Q1 2025
- 8-KTEVA
- 8-KTEVA
- 8-KTEVA
- 10-QTEVA
- 8-KTEVA
- Q4 2024
- 10-KTEVA
- 8-KTEVA
- Q3 2024
- 8-KTEVA
- 10-QTEVA
- 8-KTEVA
- Q2 2024
- 10-QTEVA
- 8-KTEVA
- Q1 2024
- 8-KTEVA
- 8-KTEVA
- 8-KTEVA
- 8-KTEVA
- 10-QTEVA
- 8-KTEVA
- Q4 2023
- 10-KTEVA
- 8-KTEVA
- Q3 2023
- 10-QTEVA
- 8-KTEVA
- 8-KTEVA
- Q2 2023
- 8-KTEVA
- 8-KTEVA
- 8-KTEVA
- 10-QTEVA
- 8-KTEVA
- Q1 2023
- 8-KTEVA
- 8-KTEVA
- 8-KTEVA
- 8-KTEVA
- 10-QTEVA
- Q4 2022
- 8-KTEVA
- 8-KTEVA
- 10-KTEVA
- 8-KTEVA
- Q3 2022
- 8-KTEVA
- 8-KTEVA
- 10-QTEVA
- Q2 2022
- 10-QTEVA
- 8-KTEVA
Earnings releases
22 documents- Q2 2026
- EX-99TEVA
- EX-99TEVA
- EX-99TEVA
- Q1 2026
- EX-99TEVA
- EX-99TEVA
- Q4 2025
- EX-99TEVA
- EX-99TEVA
- Q3 2025
- EX-99TEVA
- Q2 2025
- EX-99TEVA
- Q1 2025
- EX-99TEVA
- Q4 2024
- EX-99TEVA
- Q3 2024
- EX-99TEVA
- Q2 2024
- EX-99TEVA
- Q1 2024
- EX-99TEVA
- EX-99TEVA
- Q4 2023
- EX-99TEVA
- Q3 2023
- EX-99TEVA
- Q2 2023
- EX-99TEVA
- Q1 2023
- EX-99TEVA
- Q4 2022
- EX-99TEVA
- Q3 2022
- EX-99TEVA
- Q2 2022
- EX-99TEVA
Presentations
0 documentsNo presentations for Teva Pharmaceutical Industries are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Teva Pharmaceutical Industries are held in this edition of the library.
Mentioned by
1 companyOther tracked companies whose held documents mention Teva Pharmaceutical Industries by name or ticker. A mention is counted once per document, from the document text the library holds.
“…Y. Dauvilliers); TEVA (D. Plante). Vibrance-1 Examined the Effects of Alixorexton on Cognitive Impairment in Patients With NT1 BC-CCI = British Columbia Cognitive Complain”
See also the earnings calendar for every tracked company’s next earnings date.